IMMUNEERING CORPORATIO

Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference

27 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates

13 Nov 2024 15:05:00 By Nasdaq GlobeNewswire

Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer

15 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients

12 Sep 2024 15:05:00 By Nasdaq GlobeNewswire

Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

29 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates

06 Aug 2024 15:05:01 By Nasdaq GlobeNewswire

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer

31 Jul 2024 15:05:00 By Nasdaq GlobeNewswire

Immuneering to Present at the Jefferies Global Healthcare Conference

29 May 2024 15:05:00 By Nasdaq GlobeNewswire

Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates

07 May 2024 15:05:02 By Nasdaq GlobeNewswire

Immuneering Recognizes Melanoma Awareness Month

06 May 2024 15:30:00 By Nasdaq GlobeNewswire

IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models

09 Apr 2024 11:00:00 By Nasdaq GlobeNewswire

Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference

03 Apr 2024 15:05:00 By Nasdaq GlobeNewswire

Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations

27 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors

14 Mar 2024 06:00:00 By Nasdaq GlobeNewswire

Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors

12 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors

11 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024

05 Mar 2024 16:00:00 By Nasdaq GlobeNewswire

Immuneering to Participate in the Cowen 44th Annual Health Care Conference

04 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

01 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer

20 Feb 2024 07:00:01 By Nasdaq GlobeNewswire